Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
Our outcome data of a single-centre, heavily pre-treated cohort of Canadian patients confirm that alloSCT with post-transplant cyclophosphamide-based immunosuppression, which has been associated with improvements in PFS, remains a safe and feasible treatment option for patients with R/R HL in the era of checkpoint inhibitor use.
Authors
- Tobias Berg (ORCID: https://orcid.org/0000-0003-2668-0449)
- Brian F. Leber (ORCID: https://orcid.org/0000-0001-5502-1480)
- Irwin Walker (ORCID: https://orcid.org/0000-0003-0430-3837)
- Dina Khalaf (ORCID: https://orcid.org/0000-0002-2119-6626)
- Gwynivere A Davies (ORCID: https://orcid.org/0000-0003-4472-6535)
- R. Bhindi
- Alejandro Garcia‐Horton (ORCID: https://orcid.org/0000-0003-0579-6709)
- Shiliang Ge (ORCID: https://orcid.org/0000-0002-3072-0717)
- Kylie Lepic (ORCID: https://orcid.org/0000-0002-7287-0924)
- M Radford
Institutions
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-02-18
- DOI
- https://doi.org/10.3390/curroncol32020118
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47